Anti-tumor effect of integrin targeted 177Lu-3PRGD2 and combined therapy with endostar

Theranostics

Volumn 4, Issue 3, 2014, Pages 256-266

  Shi, Jiyun ^a   Fan, Di ^a,b   Dong, Chengyan ^a,b   Liu, Hao ^a,b   Jia, Bing ^a,b   Zhao, Huiyun ^a   Jin, Xiaona ^c   Liu, Zhaofei ^a,b   Li, Fang ^c   Wang, Fan ^a,b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

177Lu; Arg Gly Asp (RGD); Combination therapy; Integrin av 3; Radionuclide therapy

Indexed keywords

177LU; ARG-GLY-ASP (RGD); COMBINATION THERAPY.; INTEGRIN ΑVΒ3; RADIONUCLIDE THERAPY;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; COORDINATION COMPLEXES; ENDOSTATINS; FEMALE; GLIOBLASTOMA; HUMANS; INTEGRIN ALPHAVBETA3; MICE; MICE, INBRED BALB C; MICE, NUDE; PEPTIDES, CYCLIC; RADIOPHARMACEUTICALS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893625998     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.7781     Document Type: Article

References (42)

1. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nature reviews Cancer. 2011;11:239-53.
2. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005;104:1129-37.
3. Fani M, Maecke HR, Okarvi SM. Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics. 2012;2:481-501.
4. Ersahin D, Doddamane I, Cheng D. Targeted Radionuclide Therapy. Cancers. 2011;3:3838-55.
5. Veeravagu A, Liu Z, Niu G, Chen K, Jia B, Cai W, et al. Integrin v 3-Targeted Radioimmunotherapy of Glioblastoma Multiforme. Clinical Cancer Research. 2008;14:7330-9.
6. Miederer M, Henriksen G, Alke A, Mossbrugger I, Quintanilla-Martinez L, Senekowitsch-Schmidtke R, et al. Preclinical Evaluation of the -Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors. Clinical Cancer Research. 2008;14:3555-61.
7. 177Lu-DOTA0, Tyr3]Octreotate: Toxicity, Efficacy, and Survival. Journal of Clinical Oncology. 2008;26:2124-30.
8. Liu Z, Wang F, Chen X. Integrin alpha(v)beta(3)-Targeted Cancer Therapy. Drug development research. 2008;69:329-39.
9. Danhier F, Breton AL, Préat V. RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis. Molecular Pharmaceutics. 2012;121004113049007.
10. Liu Z WF, and Chen X. Integrin Targeted Delivery of Radiotherapeutics. Theranostics. 2011;1:10.
11. Beer AJ, Schwaiger M. Imaging of integrin alphavbeta3 expression. Cancer metastasis reviews. 2008;27:631-44.
12. Yin Zhang YY, Weibo Cai. Multimodality Imaging of Integrin avß3 Expression. Theranostics. 2011;1:13.
13. Gaertner FC, Kessler H, Wester HJ, Schwaiger M, Beer AJ. Radiolabelled RGD peptides for imaging and therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2012;39:126-38.
14. 177Lu-labeled cyclic RGDfK dimer. Amino Acids. 2009;39:111-20.
15. Shi J, Zhou Y, Chakraborty S, et al. Evaluation of 111In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability. Theranostics. 2011;1:18.
16. Janssen ML, Oyen WJ, Dijkgraaf I, Massuger LF, Frielink C, Edwards DS, et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res. 2002;62:6146-51.
17. Sudipta Chakraborty JS, Young-Seung Kim, Yang Zhou, Bing Jia, Fan Wang, and Shuang Liu. Evaluation of 111In-Labeled Cyclic RGD Peptides: Tetrameric not Tetravalent. Bioconjugate Chem. 2010;21:10.
18. Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, Liu S, et al. microPET imaging of glioma integrin {alpha}v{beta}3 expression using 64Cu-labeled tetrameric RGD peptide. J Nucl Med. 2005;46:1707-18.
19. Li ZB, Cai W, Cao Q, Chen K, Wu Z, He L, et al. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med. 2007;48:1162-71.
20. Liu Z, Liu S, Wang F, Liu S, Chen X. Noninvasive imaging of tumor integrin expression using 18F-labeled RGD dimer peptide with PEG4 linkers. Eur J Nucl Med Mol Imaging. 2009;36:1296-307.
21. Shi J, Wang L, Kim YS, Zhai S, Liu Z, Chen X, et al. Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J Med Chem. 2008;51:7980-90.
22. Shi J, Kim YS, Zhai S, Liu Z, Chen X, Liu S. Improving tumor uptake and pharmacokinetics of 64Cu-labeled cyclic RGD peptide dimers with Gly3 and PEG4 linkers. Bioconjug Chem. 2009;20:750-9.
23. Liu Z, Jia B, Shi J, Jin X, Zhao H, Li F, et al. Tumor Uptake of the RGD Dimeric Probe 99mTc-G3-2P4-RGD2 is Correlated with Integrin avß3 Expressed on both Tumor Cells and Neovasculature. Bioconjugate Chem. 2010;21:548-55.
24. 2 for Integrin Targeted Radionuclide Therapy. Molecular Pharmaceutics. 2011;8:591-9.
25. Ma Q, Ji B, Jia B, Gao S, Ji T, Wang X, et al. Differential diagnosis of solitary pulmonary nodules using (9)(9)mTc-3P(4)-RGD(2) scintigraphy. Eur J Nucl Med Mol Imaging. 2011;38:2145-52.
26. 2. J Nucl Med. 2012.
27. 2 for integrin receptor imaging of lung cancer: a multicenter study. J Nucl Med. 2012;53:716-22.
28. Schmidt NO, Ziu M, Carrabba G, Giussani C, Bello L, Sun Y, et al. Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficiency and survival in an orthotopic human glioblastoma model. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004;10:1255-62.
29. 177Lu-labeled monomeric, dimeric and multimeric RGD peptides for the therapy of tumors expressing a(?)ß(3) integrins. Journal of Labelled Compounds and Radiopharmaceuticals. 2012;55:140-8.
30. Ke Q-H, Zhou S-Q, Huang M, Lei Y, Du W, Yang J-Y. Early Efficacy of Endostar Combined with Chemoradiotherapy for Advanced Cervical Cancers. Asian Pacific Journal of Cancer Prevention. 2012;13:923-6.
31. Chamberlain MC, Cloughsey T, Reardon DA, Wen PY. A novel treatment for glioblastoma: integrin inhibition. Expert review of neurotherapeutics. 2012;12:421-35.
32. Lee JH, Song JH, Lee SN, Kang JH, Kim MS, Sun DI, et al. Adjuvant Postoperative Radiotherapy with or without Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: The Importance of Patient Selection for the Postoperative Chemoradiotherapy. Cancer research and treatment: official journal of Korean Cancer Association. 2013;45:31-9.
33. Lee FT, Mountain AJ, Kelly MP, Hall C, Rigopoulos A, Johns TG, et al. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005;11:7080s-6s.
34. Dumont RA, Tamma M, Braun F, Borkowski S, Reubi JC, Maecke H, et al. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin. J Nucl Med. 2013;54:762-9.
35. Liang J, E M, Wu G, Zhao L, Li X, Xiu X, et al. Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial. OncoTargets and therapy. 2013;6:1589-96.
36. Robertson R, Germanos MS, Manfredi MG, Smith PG, Silva MD. Multimodal imaging with (18)F-FDG PET and Cerenkov luminescence imaging after MLN4924 treatment in a human lymphoma xenograft model. J Nucl Med. 2011;52:1764-9.
37. 177Lu-DOTATATE therapy: survival of the fittest? Eur J Nucl Med Mol Imaging. 2011;38:1785-7.
38. Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocrine-related cancer. 2010;17:R53-73.
39. Lewis JS WM, Laforest R, Wang F, Erion JL, Bugaj JE, Srinivasan A, Anderson CJ. Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model. Int J Cancer. 2001;94:5.
40. Yoshimoto M, Ogawa K, Washiyama K, Shikano N, Mori H, Amano R, et al. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide. Int J Cancer. 2008;123:709-15.
41. Peng F, Xu Z, Wang J, Chen Y, Li Q, Zuo Y, et al. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PloS one. 2012;7:e34646.
42. 2 in human glioblastoma xenografts and orthotopic tumors. Abstract Book Supplement to the Journal of Nuclear Medicine. 2013;54:1.